You are here

Enhancement to Leak Free Non-Invasive Ventilation Mask for Infectious Patients

Award Information
Agency: Department of Health and Human Services
Branch: Centers for Disease Control and Prevention
Contract: 1R43OH012421-01
Agency Tracking Number: R43OH012421
Amount: $259,354.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CDC
Solicitation Number: PA-21-259
Timeline
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-09-01
Award End Date (Contract End Date): 2023-02-28
Small Business Information
16 Great Hollow Rd
Hanover, NH 00000-3755
United States
DUNS: 072021041
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Daniel Mika
 (603) 643-3800
 djm@creare.com
Business Contact
 Denise DuCharme
Phone: (603) 640-2341
Email: contractsmgr@creare.com
Research Institution
N/A
Abstract

PROJECT SUMMARY/ABSTRACT: A large number of patients with infectious respiratory diseases such as COVID-19 and SARS require respiratory support. Noninvasive Positive Pressure Ventilation (NPPV) via a mask is an appropriate treatment for many patients that can lead to better outcomes than intubation. Additionally, the equipment used for NPPV (such as CPAP machines) is widely available, making NPPV well suited for responding to outbreaks and pandemics. Unfortunately, NPPV masks increase the risk of disease transmission by spreading contaminated aerosols leaking from the mask seal. This exposes health care workers and other patients to increased risk and can hamper efforts to contain outbreaks of infectious diseases. The objective of this program is to develop an innovative NPPV patient interface that eliminates the leakage of contaminated aerosols through the mask seal. We propose to enhance Creare's novel leak-free mask technology to make it easier and more practical to use in a critical care setting. Our device will be cost effective and integrate easily with existing CPAP machines widely used in hospitals. This will enable widespread use of NPPV therapy on infectious patients while protecting health care workers and other patients. This technology will be a critical tool for treating patients while preventing the spreading of infectious respiratory diseases in a hospital setting. In the Phase I program, we will demonstrate the viability of our enhanced technology through building and testing laboratory prototypes.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government